Trials / Completed
CompletedNCT00096603
A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g
An Open Label, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 450 (planned)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is an open label, multicenter study designed to evaluate the safety and tolerability of efalizumab administered subcutaneously at weekly doses of 1.0 mg/kg in subjects with plaque psoriasis who previously participated in Study ACD2600g.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Raptiva (efalizumab) |
Timeline
- Start date
- 2002-10-01
- Completion
- 2004-07-01
- First posted
- 2004-11-15
- Last updated
- 2014-03-20
Source: ClinicalTrials.gov record NCT00096603. Inclusion in this directory is not an endorsement.